Sulfate and methyldopa metabolism: Metabolite patterns and platelet phenol sulfotransferase activity

Publisher Website
Google Scholar
Abstract
Sulfate conjugation catalyzed by phenol sulfotransferase (PST) is the major metabolic pathway for methyldopa. Methyldopa is also O-methylated in a reaction catalyzed by catechol-O-methyltransferase (COMT). Whether sodium sulfate alters methyldopa metabolism was determined. Methyldopa powder, 3.5 mg/kg, was taken with and without sodium sulfate, 13.25 mg/kg , by 24 subjects in a randomized, crossover design. Compared with results obtained when only methyldopa was taken, sodium sulfate taken with methyldopa increased the proportion of drug excreted as methyldopa sulfate expressed as the percentage of all urinary metabolites (66.0% .+-. 5.3% and 50.1% .+-. 7.5%; .hivin.X .+-. SD). The percentage of free methyldopa excreted also decreased (17.1% .+-. 3.7% and 27.3% .+-. 5.5%). Platelet PST and red blood cell COMT activities were measured in blood samples from these subjects. When sodium sulfate was taken with methyldopa, there was a significant correlation between platelet PST activities and percentages of metabolites excreted as methyldopa sulfate (r = 0.545; P < 0.01). This correlation was not significant when methyldopa was taken alone (r = 0.340; P > 0.10). There was a significant correlation between red blood cell COMT activities and the proportion of urinary metabolite when it was taken with sodium sulfate (r = 0.153; P > 0.20). Variation in sulfate availability may be 1 factor responsible for individual differences in the metabolism of clinically used doses of methyldopa. Platelet PST activity correlates with individual variations in the sulfate conjugation of methyldopa taken by mouth with sodium sulfate [methyldopa is a common antihypertensive drug].